Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The need for efficient and safe therapy to improve such metabolic diseases as obesity and type 2 diabetes mellitus is currently unmet. The development of dual GIPR-GLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes. Combined activation of both receptors may act synergistically providing additive effects on glucose and body weight in comparison of GLP1 analogues alone. Preclinical studies have confirmed that GIPR-GLP1R coagonists improve several hallmarks of metabolic syndrome, such as obesity, hyperglycemia, and dyslipidemia. These metabolic benefits have been translated from mice to nonhuman primates and humans. Recent clinical trials have shown that coagonists induce significant benefits on body weight, fasting, and postprandial glucose levels, insulin sensitivity, and total cholesterol. Combined GIP- and GLP1R activators have the potential to become a treatment option for patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164
Lean, M. E. J., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30068-3 · Cited by 1,017
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 11×
“39 Notes: Adapted from Molecular Metabolism, Vol 18, Coskun T, Sloop KW, Loghin C, et al, LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept, Pages 3-14, Copyright (2018), with permission from Elsevier.39 Adapted from Cell M…”
BackgroundMethodInfluentialGutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 16×
“Until recently (and in contrast to GLP1receptor [GLP1R] agonists), GIP had not been considered a suitable candidate for the treatment of T2D.”
BackgroundInfluentialThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Impaired Pulsatile Secretion of Insulin in Relatives of Patients with Non-Insulin-Dependent Diabetes
O'Rahilly, S., Turner, R. C., & Matthews, D. R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805123181902 · Cited by 540
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · cited 3×
“The important contribution of GIP to the incretin effect has been also emphasized by the observation that in patients with T2D with reduced incretin effect, the insulinotropic effect of GIP was lost, while that of GLP1 was relatively preserved.(16,21) Importantly, the reduction of chronic hyperglycemia in patients wit…”
BackgroundResultNauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344 · cited 1×
“The importance of GIP has also been demonstrated by a weak reduction in incretin effect when exendin (9–39) amide (a GLP1R antagonist) was infused during an oral glucose load.(31) Conversely, it must be mentioned that inhibition of DPP4 increases levels of both active GLP1 and GIP during improvement in glucose levels…”
BackgroundFrias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321 · cited 1×
“8 mg (as an open-label reference arm, Table 2).(43) At baseline, clinical characteristics of the patients randomized to three groups (54.”
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229
Anglerfish islet pre-proglucagon II. Nucleotide and corresponding amino acid sequence of the cDNA
Lund, P. K., Goodman, R. H., Montminy, M. R., Dee, P. C., & Habener, J. F. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)32858-8 · Cited by 146 · cited 1×
“Structures of the main incretin hormones, GIP and GLP1, were discovered in the 1980s.(17,18) GLP1 and GIP are secreted by intestinal L cells (whose abundance increases toward the ileum and the colon) and K cells (present mainly in the duodenum and the upper jejunum), respectively.”
BackgroundSchmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13024 · Cited by 74 · cited 1×
“5 mg) or placebo for 14 days in a randomized, double-blind, dose-escalation study (Table 2).(42) Patients in the study were predominantly men (52%), aged 32–65 years, and had body-mass index (BMI) values of 26.”
MethodPortron, A., Jadidi, S., Sarkar, N., DiMarchi, R., & Schmitt, C. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13025 · Cited by 46
Cited by
Karagiannis, T., Avgerinos, I., Liakos, A., Del Prato, S., Matthews, D. R., Tsapas, A., & Bekiari, E. (2022) · Diabetologia · doi:10.1007/s00125-022-05715-4 · Cited by 272
“The combined GLP-1 and GIP receptor activation has been examined recently as a promising therapeutic concept, given that the two incretins can act on pancreatic beta cells both synergistically and complementarily through distinct metabolic effects [7].”
BackgroundKabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
Wang, L. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s358989 · Cited by 56
Verhaegen, A. A., & Van Gaal, L. F. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00419-5 · Cited by 53
Zhou, Q., Lei, X., Fu, S., Liu, P., Long, C., Wang, Y., Li, Z., Xie, Q., & Chen, Q. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01198-4 · Cited by 55
Metadata
- Authors
- Bastin, M., & Andreelli, F.
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2019-09
- Volume
- Volume 12
- Pages
- 1973-1985
- ISSN
- 1178-7007 (ISSN-L)
- OpenAlex
- W2977241506
- Cited by
- 62
- References
- 24
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.